Condition
Neuroendocrine Tumor GEP Grade 1-3
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02088645Phase 1Active Not Recruiting
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
NCT07185672Phase 3Recruiting
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
NCT06981455Recruiting
Life Following Excision of Neuroendocrine Tumors
Showing all 3 trials